Study Produces Mixed Results on Alzheimer's
WEDNESDAY, March 7 (HealthDay News) -- A new study offers up
mixed results about two medications used to treat the symptoms of
the memory-robbing disease known as Alzheimer's.
While patients didn't get a major mental boost when doctors
added the drug Namenda to their regimen when they were already
taking Aricept, they did find that continuing Aricept -- a commonly
prescribed drug for Alzheimer's in the United States -- seemed to
The results, which appear in the March 8 issue of the
New England Journal of Medicine, may seem a bit murky, especially because it's difficult to measure the effects of the drugs on day-to-day living. However, study author Dr. Robert Howard, a professor of old age psychiatry and psychopathology at the Institute of Psychiatry at King's College London, said both drugs are worth taking, possibly even together.
"While these drugs will not stop or slow down the tragic course of Alzheimer's disease, they can continue to improve symptoms as the disease becomes more severe," Howard said. "If you can, try to stay on them. The benefits are tangible and, if anything, seem to get larger as the illness progresses."
While Alzheimer's disease is incurable, several drugs are
available to treat symptoms such as memory loss in patients with
mild to moderate forms of the illness. It's not clear, however,
what happens as the disease worsens.
In the new study, British researchers assigned 295 Alzheimer's
patients with moderate to severe disease to one of four groups. All
had been on the drug Aricept (donepezil). The patients either
continued the drug; stopped the drug; stopped it and started
Namenda (memantine); or they continued taking Aricept and started
taking Namenda, too.
The study, which lasted for a year, was funded by the U.K.
Medical Research Council and the U.K. Alzheimer's Society.
Patients who continued on Aricept had less impairment than those
who didn't; the improvement was equal to about three to four months
of decline, Howard said. "That's a noticeable difference for
patients, caregivers and their doctors."
However, there didn't seem to be any significant benefit to
taking both drugs. That contradicted a previous study that found
there was a benefit, said Dr. Lon Schneider, a professor of
psychiatry, neurology and gerontology at the University of Southern
California Keck School of Medicine, who wrote a commentary
accompanying the study.
Aricept can be a difficult drug to tolerate. About half of those
who take it will quit due to side effects, Schneider explained.
Those side effects include anorexia, weight loss, heart trouble and
The findings could be interpreted in various ways, Schneider
noted. The study provides evidence to support continuing Aricept,
he said, and suggests that it may not be not necessary to start
Schneider said he doubts the research would have a major impact
by decreasing how often the drugs are prescribed. Still, the
findings allow people to understand how much of an effect patients
might encounter if they go off Aricept, he noted.
For more about
Alzheimer's disease, visit the U.S. National Library of Medicine.
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.